FRAZER, Pa. (AP) -- Biotechnology company Cephalon Inc. said Friday its executive vice president of worldwide pharmaceutical operations, Robert P. Roche Jr., resigned to pursue "other longstanding interests."
The resignation is effective Feb. 5. Roche has headed pharmaceutical operations since 1995.
The company will announce plans for its leadership and the commercial organization in the near future, it said.
Cephalon's key drugs include Nuvigil, which is approved to treat narcolepsy, excessive sleepiness caused by sleep apnea, and changes in work schedule. The drug is under Food and Drug Administration review as a potential treatment for jet lag.
Shares of Cephalon fell 37 cents to $63.14 in morning trading Friday.
